Recent Updates
Recently added Catalysts
PHGE Positive Sentiment

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

Key Takeaway: BiomX Inc. will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Jonathan Solomon will lead the presentation, showcasing the company's advancements in phage therapies targeting specific pathogenic bacteria. The conference offers opportunities for engagement, including a webcast and chances for investor meetings.
Price reaction · baseline $74.1 (2023-09-05 close) · hit after-hours · 1 other PHGE headline(s) in the window, move may be shared
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • BiomX is set to present at a prestigious global investment conference.
  • The presentation will showcase their innovative phage therapies targeting pathogenic bacteria.
  • The opportunity for investor engagement through one-on-one meetings and Q&A.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+190%
120-day peak, hindsight
Typical move
13.4%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
BX002-A
Phase 1 · Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.
H.C Wainwright Global Investment Conference – September 11-13 , 202 3
Date & Time: Monday, September 11, 7:00 AM ET (available on-demand)
Presenter: Jonathan Solomon
Webcast: https://journey.ct.events/view/280bc5c9-b536-4cb2-ac47-8623a4e6ecb9
Once the presentation becomes available on-demand, registered attendees can submit their questions for the Company. To schedule a 1x1 investor meeting with the Company, please send an email to meetings@hcwco.com.
A webcast of the presentation will also be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcast will be archived on the BiomX website.
BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
LifeSci Advisors, LLC
Corporate Project Manager

Frequently Asked Questions

When is BiomX presenting at the investment conference?

BiomX will present at the H.C. Wainwright Conference from September 11-13, 2023.

Who will represent BiomX at the conference?

Jonathan Solomon, the CEO of BiomX, will be the presenter.

How can I watch the BiomX presentation?

The presentation will be available on-demand via a webcast on BiomX's website.

What therapies is BiomX developing?

BiomX is developing natural and engineered phage therapies targeting pathogenic bacteria.

How do I schedule a meeting with BiomX?

To schedule a 1x1 meeting, email meetings@hcwco.com.

Last updated: Sep 6, 2023